Aurora Spine (TSXV:ASG) Common Stock : C$37.47 Mil (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Aurora Spine Common Stock?

Aurora Spine's quarterly common stock increased from Mar. 2024 (C$37.44 Mil) to Jun. 2024 (C$37.91 Mil) but then declined from Jun. 2024 (C$37.91 Mil) to Sep. 2024 (C$37.47 Mil).

Aurora Spine's annual common stock increased from Dec. 2021 (C$32.11 Mil) to Dec. 2022 (C$34.26 Mil) and increased from Dec. 2022 (C$34.26 Mil) to Dec. 2023 (C$37.11 Mil).

Aurora Spine Common Stock Historical Data

The historical data trend for Aurora Spine's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurora Spine Common Stock Chart

Aurora Spine Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

27.22

28.19

32.11

34.26

37.11

Aurora Spine Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Common Stock	Get a 7-Day Free Trial															35.32	37.11	37.44	37.91	37.47

Aurora Spine Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Aurora Spine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aurora Spine Corp (TSXV:ASG) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

ASAPF:USA

Address

20 Holly Street, Suite 300, Toronto, ON, CAN, M4S 3B1

Website

https://www.aurora-spine.com

Aurora Spine Corp is engaged in the business of the development and commercialization of minimally invasive interspinous fusion systems and devices. The product portfolio includes implants, surgical tools, and biologics. It derives revenues primarily from the sale of spinal surgery implants, consumable products used in spinal surgeries, and service revenue for referring products to its customers.

Executives